We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Mr
Martin
Kaiser
martin.kaiser@icr.ac.uk
Alison
Turner
Alison.Turner3@rmh.nhs.uk
Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
OASIS is a multi-centre tissue and data collection study for patients with symptomatic multiple myeloma that ultimately aims at identifying novel future therapies for patients with an unmet clinical need. The patient blood and bone marrow material collected in the study is used for laboratory cell culture drug testing to pre-clinically identify the most promising drug candidates for future clinical development. Patient material will also be tested to identify molecular features, e.g. gene mutations, of the tumour that could predict response to a specific therapy. This could speed up a future clinical development plan in the sense of tailored, stratified therapy. Outcome data of participants will be collected and also correlated with molecular features of the tumour to identify groups of patients that have an unmet clinical need when treated with standard therapies on the NHS. These groups will be prioritised for the future molecularly stratified clinical drug development programs. Patients may be informed about results of the molecular tumour testing if it may open therapeutic options for them, e.g. a molecularly targeted clinical trial for tumours with a specific mutation. A sub-group of 100 patients will also have blood samples taken for cfDNA following 6 cycles of induction therapy/ASCT for evaluation of novel testing strategies.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Management of Care;
You can take part if:
You may not be able to take part if:
Patients under the age of 18. Patients unable or unwilling to give consent. Patients who are registered in the study on the basis of a suspected new diagnosis of myeloma but are subsequently found not to have myeloma will be excluded and not followed up within the study.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Institute of Cancer Research: Royal Cancer Hospital and funded by Myeloma UK; NIHR Biomedical Research Centre at The Royal Marsden and the ICR; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 41723
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
